Bemiparin sodium

Drug Profile

Bemiparin sodium

Alternative Names: Anti-Factor Xa - Rovi; Badyket; Cibor; Hepadren; Heporax; Hibor; Ivor; Ivorat; Ivormax; LMWH-Rovi; Nautiol; RO-11; Zibor

Latest Information Update: 07 May 2015

Price : $50

At a glance

  • Originator Rovi
  • Developer Berlin Chemie; Elder Pharmaceuticals; Menarini; Rovi; sigma-tau SpA; UCB; University of Navarra
  • Class Antithrombotics; Glycosaminoglycans; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Small cell lung cancer

Highest Development Phases

  • Marketed Thromboembolism
  • Phase II Small cell lung cancer
  • Discontinued Diabetic foot ulcer

Most Recent Events

  • 07 May 2015 Rovi is still seeking a partner for the continued clinical development of bemiparin for Small cell lung cancer
  • 07 May 2015 Launched for Thromboembolism in Ecuador, China, Hong Kong, Brazil, Peru, Bolivia, Chile, South Africa, Sudan, Egypt, Libya, Algeria, Morocco, South Korea, Indonesia, Kazakhstan, Syria, Israel, Lebanon, Jordan, Switzerland, Belarus, Romania, Moldova, Albania, Bosnia-Herzegovina, Croatia, Serbia, Slovakia, Saudi Arabia, Qatar, United Arab Emirates, Oman, Yemen, Iraq, Iran, Pakistan, Turkmenistan, Turkmenistan, Uzbekistan, Kyrgyzstan, Azerbaijan, Armenia and Tajikistan (SC)
  • 30 Jul 2014 Registered for Thromboembolism in China before July 2014 (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top